Related references
Note: Only part of the references are listed.Exquisitely Specific anti-KRAS Biodegraders Inform on the Cellular Prevalence of Nucleotide-Loaded States
Shuhui Lim et al.
ACS CENTRAL SCIENCE (2021)
KRAS Secondary Mutations That Confer Acquired Resistance to KRAS G12C Inhibitors, Sotorasib and Adagrasib, and Overcoming Strategies: Insights From In Vitro Experiments
Takamasa Koga et al.
JOURNAL OF THORACIC ONCOLOGY (2021)
Selective and noncovalent targeting of RAS mutants for inhibition and degradation
Kai Wen Teng et al.
NATURE COMMUNICATIONS (2021)
Clinical Acquired Resistance to KRASG12C Inhibition through a novel KRAS Switch-II Pocket Mutation and Polyclonal Alterations Converging on RAS-MAPK Reactivation
Noritaka Tanaka et al.
CANCER DISCOVERY (2021)
Development of a High-throughput NanoBRET Screening Platform to Identify Modulators of the RAS/RAF Interaction
David E. Durrant et al.
MOLECULAR CANCER THERAPEUTICS (2021)
Acquired Resistance to KRASG12C Inhibition in Cancer
M. M. Awad et al.
NEW ENGLAND JOURNAL OF MEDICINE (2021)
Drugging the Undruggable: Advances on RAS Targeting in Cancer
Miriam Molina-Arcas et al.
GENES (2021)
1H, 15N backbone assignment and comparative analysis of the wild type and G12C, G12D, G12V mutants of K-Ras bound to GDP at physiological pH
Gyula Palfy et al.
BIOMOLECULAR NMR ASSIGNMENTS (2020)
Discovery of a Covalent Inhibitor of KRASG12C (AMG 510) for the Treatment of Solid Tumors
Brian A. Lanman et al.
JOURNAL OF MEDICINAL CHEMISTRY (2020)
The small molecule BI-2852 induces a nonfunctional dimer of KRAS
Timothy H. Tran et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2020)
Analysis of RAS protein interactions in living cells reveals a mechanism for pan-RAS depletion by membrane-targeted RAS binders
Yao-Cheng Li et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2020)
Identification of the Clinical Development Candidate MRTX849, a Covalent KRASG12C Inhibitor for the Treatment of Cancer
Jay B. Fell et al.
JOURNAL OF MEDICINAL CHEMISTRY (2020)
Quantifying CDK inhibitor selectivity in live cells
Carrow I. Wells et al.
NATURE COMMUNICATIONS (2020)
RAS-targeted therapies: is the undruggable drugged?
Amanda R. Moore et al.
NATURE REVIEWS DRUG DISCOVERY (2020)
Real-Time In-Cell NMR Reveals the Intracellular Modulation of GTP-Bound Levels of RAS
Qingci Zhao et al.
CELL REPORTS (2020)
GTP-State-Selective Cyclic Peptide Ligands of K-Ras(G12D) Block Its Interaction with Raf
Ziyang Zhang et al.
ACS CENTRAL SCIENCE (2020)
Drugging an undruggable pocket on KRAS
Dirk Kessler et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2019)
The clinical KRAS(G12C) inhibitor AMG 510 drives anti-tumour immunity
Jude Canon et al.
NATURE (2019)
Targeting KRAS Mutant Cancers with a Covalent G12C-Specific Inhibitor
Matthew R. Janes et al.
CELL (2018)
The reactivity-driven biochemical mechanism of covalent KRAS(G12C) inhibitors
Rasmus Hansen et al.
NATURE STRUCTURAL & MOLECULAR BIOLOGY (2018)
The reactivity-driven biochemical mechanism of covalent KRAS(G12C) inhibitors
Rasmus Hansen et al.
NATURE STRUCTURAL & MOLECULAR BIOLOGY (2018)
Crystal Structure of a Human K-Ras G12D Mutant in Complex with GDP and the Cyclic Inhibitory Peptide KRpep-2d
Satoshi Sogabe et al.
ACS MEDICINAL CHEMISTRY LETTERS (2017)
Investigation of the structural requirements of K-Ras(G12D) selective inhibitory peptide KRpep-2d using alanine scans and cysteine bridging
Ayumu Niida et al.
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS (2017)
K-Ras(G12D)-selective inhibitory peptides generated by random peptide T7 phage display technology
Kotaro Sakamoto et al.
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS (2017)
NanoLuc Complementation Reporter Optimized for Accurate Measurement of Protein Interactions in Cells
Andrew S. Dixon et al.
ACS CHEMICAL BIOLOGY (2016)
CcpNmr AnalysisAssign: a flexible platform for integrated NMR analysis
Simon P. Skinner et al.
JOURNAL OF BIOMOLECULAR NMR (2016)
Direct small-molecule inhibitors of KRAS: from structural insights to mechanism-based design
Jonathan M. L. Ostrem et al.
NATURE REVIEWS DRUG DISCOVERY (2016)
Allele-specific inhibitors inactivate mutant KRAS G12C by a trapping mechanism
Piro Lito et al.
SCIENCE (2016)
Selective Inhibition of Oncogenic KRAS Output with Small Molecules Targeting the Inactive State
Matthew P. Patricelli et al.
CANCER DISCOVERY (2016)
Seeing is believing: Ras dimers observed in live cells
Mark R. Philips et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2015)
Ras-GTP dimers activate the Mitogen-Activated Protein Kinase (MAPK) pathway
Xiaolin Nan et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2015)
Target engagement and drug residence time can be observed in living cells with BRET
Matthew B. Robers et al.
NATURE COMMUNICATIONS (2015)
K-Ras(G12C) inhibitors allosterically control GTP affinity and effector interactions
Jonathan M. Ostrem et al.
NATURE (2013)
NMR-based functional profiling of RASopathies and oncogenic RAS mutations
Matthew J. Smith et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2013)
Assignments of backbone 1H, 13C and 15N resonances in H-Ras (1-166) complexed with GppNHp at physiological pH
Casey O'Connor et al.
BIOMOLECULAR NMR ASSIGNMENTS (2012)
Small-molecule ligands bind to a distinct pocket in Ras and inhibit SOS-mediated nucleotide exchange activity
Till Maurer et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2012)
Organization, dynamics, and segregation of Ras nanoclusters in membrane domains
Lorant Janosi et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2012)
Ras nanoclusters: Molecular structure and assembly
Daniel Abankwa et al.
SEMINARS IN CELL & DEVELOPMENTAL BIOLOGY (2007)
Share Paper
